Source: The Lancet Oncology Author: Julie B Schnur Quality of life is broadly recognized within oncology as an essential component of cancer care and has been studied extensively in patients with breast cancer.1 Yet, among the three pillars of breast cancer treatment (surgery, chemotherapy, and radiotherapy), research on radiotherapy-related quality of life has lagged behind. Specifically, the [...]
Continue reading...Friday, January 22, 2010
Source: Irishtimes Author: Mary Carolan The HSE has apologised to the family of a deceased 59 year old man after admitting a two year delay in diagnosing his cancer and is also to pay over some €102,000 under a settlement of High Court proceedings. John McNeive, Logalisheen, Ballindine, Co Mayo, died in August 2005 four months after he [...]
Continue reading...Tuesday, November 17, 2009
Source: professional.cancerconsultants.com Author: staff A multicenter randomized trial has shown that patients with locoregionally advanced head and neck cancer receiving adjuvant Erbitux® (cetuximab) and radiotherapy who develop a rash have a better survival than patients receiving this therapy who don’t develop a rash. The details of this five-year follow-up of a Phase III randomized study were [...]
Continue reading...Monday, November 16, 2009
Source: www.northamptonchron.co.uk Author: staff A mouth cancer patient who was told he had only a year to live is celebrating after being given the all clear from doctors. In May this year, Brian Barford was given the awful news after he had been referred by a dentist to Northampton General Hospital where he was told he had mouth [...]
Continue reading...Thursday, November 5, 2009
Source: www.medscape.com Author: Zosia Chustecka In patients with head and neck cancer who do not undergo surgery, chemotherapy with nonplatinum agents given concurrently with radiotherapy offers clear benefits for recurrence and survival, say the authors of one of the largest and longest randomized trials carried out in this patient group. Event-free survival in patients who received concomitant chemoradiation [...]
Continue reading...Tuesday, November 3, 2009
Source: www.reuters.com Author: press release YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that an oral presentation at the American Society for Therapeutic Radiology and Oncology (ASTRO) 2009 Annual Meeting reported positive 48-month survival data for its EGFR-targeting antibody, [...]
Continue reading...Monday, September 28, 2009
Source: Author: Dad Tim Gallego feels like a new man after having his face rebuilt from different parts of his body. Financial adviser Tim, 46, had 16 operations to reshape his face after he was hit with disfiguring mouth cancer. Bones from his ribs and hips were used to form a new nose and jaw. Arteries from his legs [...]
Continue reading...Saturday, August 22, 2009
Source: www.mirror.co.uk Author: staff Surgeons have successfully carried out the world’s first face, jaw and tongue transplant. They spent 16 hours operating on a man of 43 whose face had been horribly disfigured by radiotherapy for a tumour 11 years ago. The patient will eventually be able to eat, taste, swallow and speak again. Pedro Cavadas, who led 30 Spanish [...]
Continue reading...Friday, July 3, 2009
Source: speech-language-pathology-audiology.advanceweb.com Author: staff Cancer and its therapies, including chemotherapy and radiotherapy, may directly alter and damage taste and odor perception, possibly leading to patient malnutrition, and in severe cases, significant morbidity, according to a Virginia Tech – Wake Forest University Comprehensive Cancer Center compilation of various existing studies [Journal of Supportive Oncology, 7(2): 58-65]. One of the [...]
Continue reading...Friday, April 17, 2009
Source: Journal of Clinical Oncology, Vol 27, No 12 (April 20), 2009: pp. 1992-1998 Authors: Pernille Lassen et al. Purpose: A subset of head and neck cancers is associated with the human papillomavirus (HPV). Viral infection is closely correlated with expression of p16INK4A in these tumors. We evaluated p16INK4A as a prognostic marker of treatment response and survival [...]
Continue reading...
Thursday, March 4, 2010
0 Comments